GO:0045787 positive regulation of cell cycle: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045787 (positive regulation of cell cycle) describes any process that activates or increases the rate or extent of progression through the cell cycle.
• MYC is a master transcriptional amplifier of cell cycle progression, driving expression of cyclins, CDKs, and E2F targets.
• MDM2 can promote cell cycle progression in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1-dependent pathways.
• Cell cycle checkpoint gene expression signatures correlate with prognosis, immune regulation, and therapeutic response in colorectal adenocarcinoma.
• Mitochondrial proteins such as SLC25A43 and chromatin remodelers such as Fun30 provide non-canonical inputs into positive cell cycle regulation.
• CDK7 and CDK9 coordinate transcription with cell cycle checkpoint control, linking RNA polymerase II activity to proliferation.
Description
Positive regulation of cell cycle (GO:0045787) is a biological process ontology term defined as any process that activates or increases the rate or extent of progression through the cell cycle. This term captures the integrated signaling, transcriptional, and post-translational events that commit a cell to divide and ensure timely passage through G1, S, G2, and M phases. Because uncontrolled proliferation is a hallmark of cancer and because regenerative medicine depends on controlled expansion of progenitor cells, understanding the positive regulators of the cell cycle is central to both basic and translational research. The QuickGO definition emphasizes activation or increase in rate or extent, distinguishing this term from negative regulation (GO:0045786) and from the broader cell cycle process itself. Mechanistically, positive regulation is achieved through transcriptional induction of cyclins and CDKs, inactivation of checkpoint inhibitors, and metabolic or mitochondrial permissive signals. For example, MYC acts as a transcriptional amplifier that drives expression of numerous cell cycle genes, thereby increasing the overall rate of proliferation. In parallel, MDM2 can promote cell cycle progression in prostate cancer cells via Aurora Kinase-B and p21WAF1/CIP1-mediated pathways, illustrating how a single oncoprotein can rewire multiple cell cycle modules. Transcriptomic studies in colorectal adenocarcinoma have shown that cell cycle checkpoint gene expression correlates with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response, underscoring the clinical relevance of this process. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0045787, its key genes, regulatory inputs, disease links, and experimental methods for studying it.
positive regulation of cell cycle At A Glance
| GO ID | GO:0045787 |
|---|---|
| GO term | positive regulation of cell cycle |
| Ontology | biological_process |
| Synonym | activation of progression through cell cycle; positive regulation of cell cycle progression; positive regulation of progression through cell cycle; stimulation of progression through cell cycle; up regulation of progression through cell cycle; up-regulation of progression through cell cycle; upregulation of progression through cell cycle |
| Major function | Activates or increases the rate or extent of progression through the cell cycle. |
| Related process | Cell cycle (GO:0007049), negative regulation of cell cycle (GO:0045786) |
| Key regulators | MYC, MDM2, CDK7, CDK9, Aurora Kinase-B, p21WAF1/CIP1, SLC25A43, Fun30 |
| Disease relevance | Cancer, including prostate cancer and colorectal adenocarcinoma |
| Research methods | Transcriptomics, CRISPR knockout, point mutation, knock-in, overexpression, cell cycle imaging |
What Is GO:0045787?
In our own words, GO:0045787 (positive regulation of cell cycle) encompasses any molecular or cellular process that activates, accelerates, or increases the extent of cell cycle progression. It includes signals that push cells through G1/S and G2/M transitions, such as growth factor signaling, oncogene activation, and transcriptional programs that elevate cyclin-CDK activity, while opposing the effects of checkpoint inhibitors and negative regulators.
Why Is positive regulation of cell cycle Important in Cell Biology?
Positive regulation of cell cycle is fundamental to development, tissue homeostasis, and regeneration, and its dysregulation is a driving force in cancer and other proliferative disorders. Understanding the molecular players that activate cell cycle progression provides targets for therapeutic intervention and biomarkers for prognosis.
• Drives normal development and tissue regeneration by promoting controlled cell division.
• Its dysregulation leads to uncontrolled proliferation in cancers such as prostate cancer and colorectal adenocarcinoma.
• MYC-mediated transcriptional amplification of cell cycle genes is a central mechanism in many tumors.
• MDM2 can promote cell cycle progression via Aurora Kinase-B and p21WAF1/CIP1, offering therapeutic targets.
• Cell cycle checkpoint gene signatures predict prognosis and therapeutic response in colorectal cancer.
• Mitochondrial and chromatin remodeling factors add layers of regulation beyond canonical cyclin-CDK modules.
• CDK7 and CDK9 link transcription to cell cycle checkpoint control, highlighting co-targeting opportunities.
• Plant TOR signaling demonstrates evolutionary conservation of positive cell cycle regulation.
• Transcriptional dynamics are a major controller of cell cycle transition, making it a rich area for systems biology.
What Happens During positive regulation of cell cycle?
Growth factor and oncogenic signaling
In simple terms: External signals tell the cell it is time to divide.
Positive regulation begins with mitogenic signals that activate pathways such as RAS-MAPK and PI3K-AKT, leading to increased expression of cyclins and CDKs. MYC is a key downstream effector that amplifies the transcription of many cell cycle genes, thereby increasing the rate of progression through G1 and S phases. In prostate cancer cells, MDM2 can promote cell cycle progression through Aurora Kinase-B and p21WAF1/CIP1-mediated pathways, illustrating how oncoproteins directly stimulate proliferation.
Transcriptional control of cell cycle genes
In simple terms: The cell turns on a set of genes that push the cycle forward.
Transcriptional regulation is a major controller of cell cycle transition dynamics. MYC activates E2F transcription factors and induces cyclin D, E, A, and B, as well as CDK4, CDK2, and CDC25 phosphatases, collectively accelerating cell cycle progression. CDK7 and CDK9 coordinate transcription with cell cycle checkpoint regulation by phosphorylating RNA polymerase II, ensuring that proliferative gene expression is coupled to cycle progression.
Checkpoint override and inhibitor inactivation
In simple terms: The cell disables the brakes that would normally stop division.
Positive regulation often involves overcoming checkpoint barriers. MDM2 can promote cell cycle progression by modulating p21WAF1/CIP1, a CDK inhibitor, thereby releasing CDK activity. In colorectal adenocarcinoma, expression of cell cycle checkpoint genes correlates with distinct prognosis and therapeutic response, indicating that checkpoint override is clinically relevant.
Metabolic and mitochondrial inputs
In simple terms: Mitochondria provide permissive signals for division.
Mitochondrial regulation of cell cycle progression through SLC25A43 demonstrates that metabolic and mitochondrial carriers can positively influence the cell cycle. This adds a layer of regulation beyond canonical cyclin-CDK control, linking cellular energetics to proliferation.
Chromatin remodeling and DNA damage response
In simple terms: Chromatin changes help the cell cycle proceed, especially after DNA damage.
The Fun30 chromatin remodeler has cell cycle-dependent positive and negative functions in DNA damage response, showing that chromatin remodeling can promote cell cycle progression under specific conditions. This context-dependent role highlights the complexity of positive regulation.
Evolutionary conservation and TOR signaling
In simple terms: Similar mechanisms exist in plants, showing this process is ancient.
In plants, the target of rapamycin (TOR) signaling pathway controls the cell cycle, demonstrating evolutionary conservation of positive regulation mechanisms. This conservation makes model organisms valuable for studying GO:0045787.
Key Genes Involved in GO:0045787 positive regulation of cell cycle
The following genes and proteins are established positive regulators of the cell cycle, supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYC | Transcriptional amplifier of cell cycle genes; drives G1/S transition | Oncogene; target for proliferation studies and cancer therapy |
| MDM2 | Promotes cell cycle progression via Aurora Kinase-B and p21WAF1/CIP1 | Oncoprotein; therapeutic target in prostate cancer |
| Aurora Kinase-B | Mitotic kinase; downstream of MDM2 in promoting cell cycle | Target for mitotic inhibitors |
| p21WAF1/CIP1 | CDK inhibitor; modulated by MDM2 to promote cycle | Checkpoint regulator; biomarker |
| CDK7 | Phosphorylates RNA Pol II; coordinates transcription and cell cycle | Therapeutic target in cancer |
| CDK9 | Phosphorylates RNA Pol II; links transcription to cell cycle checkpoints | Target for transcriptional CDK inhibitors |
| SLC25A43 | Mitochondrial carrier; regulates cell cycle progression | Metabolic regulator; potential biomarker |
| Fun30 | Chromatin remodeler; cell cycle-dependent functions in DNA damage response | Model for chromatin and cell cycle crosstalk |
| E2F family | Transcription factors activated by MYC; drive S-phase genes | Central to G1/S transition studies |
| Cyclin D | Activates CDK4/6; promotes G1 progression | Target for CDK4/6 inhibitors |
| Cyclin E | Activates CDK2; promotes G1/S transition | Biomarker in cancer |
| CDK4 | Kinase partner of Cyclin D; phosphorylates RB | Drug target in breast cancer |
| CDK2 | Kinase partner of Cyclin E/A; drives S phase | Target for cancer therapy |
| CDC25 phosphatases | Activate CDKs by removing inhibitory phosphates | Oncogenes; therapeutic targets |
| TOR | Kinase controlling cell cycle in plants | Model for nutrient signaling and growth |
| RB | Tumor suppressor; inactivated by CDK phosphorylation | Checkpoint regulator; frequently mutated in cancer |
| p53 | Tumor suppressor; can oppose positive regulation | Guardian of the genome; mutation analysis |
How Is positive regulation of cell cycle Regulated?
Positive regulation of cell cycle is itself tightly regulated by upstream signaling pathways. The TOR pathway controls cell cycle in plants, linking nutrient availability to proliferation. In mammalian cells, MYC expression and activity are regulated by growth factors, and MYC in turn amplifies cell cycle gene transcription. MDM2 activity is modulated by p53 and other stress signals, and MDM2 can promote cell cycle progression through Aurora Kinase-B and p21WAF1/CIP1. CDK7 and CDK9 are regulated by their association with cyclin H and cyclin T, respectively, and coordinate transcription with cell cycle checkpoints. Transcriptional regulation is a major controller of cell cycle transition dynamics, indicating that feedback loops and network motifs govern the rate of progression.
positive regulation of cell cycle and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYC | Multiple cancers; oncogenic proliferation | Knockout or overexpression in cancer cell lines |
| MDM2 | Prostate cancer; cell cycle progression | Point mutation to disrupt p21 binding |
| CDK7 | Cancer; transcription-cell cycle coordination | Knockout or inhibitor treatment |
| CDK9 | Cancer; transcription-cell cycle coordination | Knockout or inhibitor treatment |
| SLC25A43 | Mitochondrial regulation of cell cycle | Knockout in mitochondrial disease models |
Cancer
Dysregulated positive regulation of cell cycle is a hallmark of cancer. MYC amplification or overexpression drives uncontrolled proliferation in many tumor types. In prostate cancer, MDM2 promotes cell cycle progression through Aurora Kinase-B and p21WAF1/CIP1 pathways, contributing to tumor growth. In colorectal adenocarcinoma, cell cycle checkpoint gene expression correlates with prognosis, molecular characteristics, immunological regulation, and therapeutic response, highlighting the clinical importance of these pathways.
Therapeutic targeting
Because positive regulators of the cell cycle are often oncogenic, they are attractive therapeutic targets. CDK7 and CDK9 inhibitors are being explored to disrupt the coordination between transcription and cell cycle checkpoints. CDK4/6 inhibitors target Cyclin D-CDK4/6 complexes, a key node in positive regulation. MDM2 inhibitors aim to restore p53 activity and block MDM2-mediated cell cycle promotion.
Metabolic and mitochondrial disorders
Mitochondrial regulation of cell cycle progression through SLC25A43 suggests that metabolic dysfunction could impact proliferative capacity. This links positive cell cycle regulation to mitochondrial biology and potentially to metabolic diseases.
From positive regulation of cell cycle-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MYC drive cell cycle gene expression? | MYC knockout or overexpression cell lines |
| How does MDM2 promote cell cycle in prostate cancer? | MDM2 point mutation (p21 binding site) |
| What is the role of CDK7 in transcription-cell cycle coupling? | CDK7 knockout or knock-in of kinase-dead mutant |
| Does SLC25A43 regulate cell cycle via mitochondrial metabolism? | SLC25A43 knockout and rescue |
| How does Fun30 chromatin remodeling affect cell cycle after DNA damage? | Fun30 knockout and tagged knock-in |
| Can cell cycle checkpoint signatures predict therapy response? | Patient-derived organoids with CRISPR screening |
How to Study the positive regulation of cell cycle Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript levels of cell cycle genes | Identify signatures and pathways |
| CRISPR knockout screen | Gene essentiality for proliferation | Discover positive regulators |
| Flow cytometry | Cell cycle phase distribution | Validate proliferation changes |
| EdU incorporation | DNA synthesis (S phase) | Measure proliferation rate |
| Western blot | Protein expression and phosphorylation | Validate cyclin/CDK changes |
| Phosphoproteomics | Kinase substrate phosphorylation | Study CDK7/CDK9 targets |
| Immunofluorescence | Subcellular localization of cell cycle proteins | Assess chromatin remodeling |
| Organoid culture | Patient-derived proliferation | Predict therapeutic response |
Transcriptomic profiling
RNA-seq and transcriptomic analyses are used to identify cell cycle gene expression signatures. In colorectal adenocarcinoma, transcriptomic correlates of cell cycle checkpoints have been linked to prognosis and therapeutic response. Transcriptional regulation is a major controller of cell cycle transition dynamics, making RNA-seq a key method.
CRISPR-based genetic screens
CRISPR knockout and activation screens can identify positive regulators of the cell cycle. For example, knocking out MYC or MDM2 and measuring proliferation can validate their roles. Library screening with cell cycle reporters enables unbiased discovery of regulators.
Cell cycle imaging and flow cytometry
Flow cytometry with DNA dyes (e.g., propidium iodide) and EdU incorporation measures cell cycle distribution and proliferation rate. These methods are used to assess the effects of manipulating genes such as CDK7 and CDK9.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify cyclin and CDK levels and phosphorylation events. This is particularly useful for studying CDK7/CDK9-mediated phosphorylation of RNA polymerase II.
How CRISPR Can Be Used to Study GO:0045787 positive regulation of cell cycle
Knockout
CRISPR knockout of positive regulators such as MYC, MDM2, CDK7, or CDK9 can reduce proliferation and cause cell cycle arrest. These models are essential for validating gene function and for identifying synthetic lethal interactions.
Point Mutation
Point mutations can dissect specific domains or phosphorylation sites. For example, mutating the p21WAF1/CIP1 binding site in MDM2 can test its role in cell cycle promotion. Kinase-dead mutations in CDK7 or CDK9 can separate kinase activity from scaffolding functions.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) allows visualization and immunoprecipitation of endogenous proteins. Tagged knock-in of Fun30 or SLC25A43 can reveal their dynamic localization during the cell cycle.
Overexpression
Overexpression of MYC or MDM2 can drive accelerated cell cycle progression and transformation. These models are useful for studying oncogenic mechanisms and for testing targeted inhibitors.
How EDITGENE Supports positive regulation of cell cycle Research
Researchers studying positive regulation of cell cycle-related genes often need to determine whether a candidate gene is causally involved in driving proliferation, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of cell cycle research.
Frequently Asked Questions About positive regulation of cell cycle
What is GO:0045787 positive regulation of cell cycle?
GO:0045787 is a Gene Ontology biological process term defined as any process that activates or increases the rate or extent of progression through the cell cycle.
What genes are involved in positive regulation of cell cycle?
Key genes include MYC, MDM2, Aurora Kinase-B, p21WAF1/CIP1, CDK7, CDK9, SLC25A43, and Fun30, among others.
How does MYC regulate the cell cycle?
MYC acts as a transcriptional amplifier that drives expression of cyclins, CDKs, and E2F targets, thereby increasing the rate of cell cycle progression.
What is the role of MDM2 in cell cycle progression?
MDM2 can promote cell cycle progression in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1-mediated pathways.
How are cell cycle checkpoints related to cancer prognosis?
In colorectal adenocarcinoma, cell cycle checkpoint gene expression correlates with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response.
What methods are used to study positive regulation of cell cycle?
Common methods include RNA-seq, CRISPR screens, flow cytometry, EdU incorporation, Western blot, and phosphoproteomics.
Can CRISPR be used to study cell cycle regulators?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in cell cycle regulation.
What is the role of CDK7 and CDK9 in the cell cycle?
CDK7 and CDK9 coordinate transcription with cell cycle checkpoint regulation by phosphorylating RNA polymerase II.
How does mitochondrial function influence the cell cycle?
Mitochondrial regulation of cell cycle progression through SLC25A43 demonstrates that mitochondrial carriers can positively influence the cell cycle.
What is the link between TOR signaling and the cell cycle?
In plants, the target of rapamycin (TOR) signaling pathway controls the cell cycle, showing evolutionary conservation of positive regulation.
Conclusion
GO:0045787 positive regulation of cell cycle is a central biological process that integrates growth signals, transcriptional programs, and metabolic inputs to drive cell division. Its dysregulation underlies cancer and other proliferative diseases, making it a prime target for therapeutic intervention. The genes and mechanisms highlighted here, from MYC and MDM2 to CDK7/CDK9 and mitochondrial factors, provide a framework for future research. EDITGENE's CRISPR services empower researchers to build precise cell models and accelerate discoveries in this vital field.
References
- 1. Bretones G et al.. 2015. Myc and cell cycle control.. Biochim Biophys Acta 1849(5):506-16 PMID: 24704206
- 2. Kanagasabai T et al.. 2020. Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1(/CIP1) mediated pathways.. Cell Signal 66:109435 PMID: 31706019
- 3. Wang H et al.. 2023. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.. Front Immunol 14:1291859 PMID: 38143740
- 4. Gabrielson M et al.. 2016. Mitochondrial regulation of cell cycle progression through SLC25A43.. Biochem Biophys Res Commun 469(4):1090-6 PMID: 26721434
- 5. Siler J et al.. 2017. Cell cycle-dependent positive and negative functions of Fun30 chromatin remodeler in DNA damage response.. DNA Repair (Amst) 50:61-70 PMID: 28089177
- 6. Lee CF et al.. 2024. The involvement of cyclin-dependent kinase 7 (CDK7) and 9 (CDK9) in coordinating transcription and cell cycle checkpoint regulation.. Cell Cycle 23(21-24):962-974 PMID: 40223539
- 7. Ahmad Z et al.. 2019. Cell cycle control by the target of rapamycin signalling pathway in plants.. J Exp Bot 70(8):2275-2284 PMID: 30918972
- 8. Romanel A et al.. 2012. Transcriptional regulation is a major controller of cell cycle transition dynamics.. PLoS One 7(1):e29716 PMID: 22238641
